Home Featured Page 136

Featured

Latest

A Practitioner Statement on the Responsible Development of Ibogaine in the United States – Open Letter

Dr. Michael Alpert and Peter Alberding – ALS, Existential Distress, and Ketamine Therapy

Pα+ Psychedelic Bulletin #223: Ibogaine Advocates Court Trump, via Rogan; Compass Launches Provider Training Grants; Therapeutic Alliance Debate Reignites

Psychedelic Funding Update: Q1 2026

Inclius Alvarious’s Place Within Indigenous Society

PsyBio Therapeutics Takes Initial Step to Help Protect the Sonoran Desert...

MIND CURE ENTERS INTO BINDING LETTER OF INTENT WITH LNG ENERGY...

Silo Pharma Issues Letter to Shareholders Detailing Progress on Pipeline Assets...

Algernon Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for Ifenprodil for...

Ehave Shareholder from CEO Ben Kaplan and Corporate Update

Braxia Scientific Reports Q2 2023 Financial Results; Focused on Growing Clinic...

Psyence Group Announces Closing of Second Tranche of Private Placement and...

Israeli Based Biotech Company Clearmind Completes IND-Enabling Studies for CMND-100

Vital 2023: Informational Session and Q&A

Psychedelic Health – New course launches to bridge the psychedelic education...

EDITOR PICKS

A Practitioner Statement on the Responsible Development of Ibogaine in the...

Dr. Michael Alpert and Peter Alberding – ALS, Existential Distress, and...

Pα+ Psychedelic Bulletin #223: Ibogaine Advocates Court Trump, via Rogan; Compass...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.